Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221461 · ClinicalTrials.gov registry record · Phase 2
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
A Phase 2 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07221461: Clinical Trial Phase 2 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
NCT07221461 is a Phase 2 study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221461, a Phase 2 study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.
Primary Outcome
Score 0 no fine lines thru 9 numerous, many fine lines
Interventions
- DEVICE Skinvive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2026-03-02 |
| Phase | Phase 2 |
What is known before NCT07221461 opens enrollment
NCT07221461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Skinvive is the first listed.
NCT07221461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07221461 about?
NCT07221461 is a clinical study titled "Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists". Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.
What is the current status of trial NCT07221461?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-11-01. Estimated completion is 2026-03-02.
What interventions are being tested in trial NCT07221461?
The interventions under investigation include: Skinvive (DEVICE).
Who is sponsoring clinical trial NCT07221461?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07221461's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI